Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265591 | 0.87 | AGTR1 (0.64) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL22533560 | 0.86 | AGTR1 (0.62) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL16456644 | 0.85 | AGTR1 (0.47) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL3975959 | 0.85 | AGTR1 (0.75) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL28927794 | 0.82 | AGTR1 (0.70) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL29257718 | 0.82 | PPARG (0.70) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL8563144 | 0.82 | AGTR1 (0.70) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL31364599 | 0.82 | PPARG (0.70) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL19380341 | 0.80 | AGTR1 (0.71) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL21083554 | 0.80 | AGTR1 (0.68) | AGTR1ABCB11EGFRERBB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | claimed |
| EP-3204362-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055582-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2016-04-14 | — | — | WO | claimed |
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | claimed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | claimed |
| EP-1885714-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK Pharmaceuticals D.D. (SI) | 2008-02-13 | — | — | EP | claimed |
| WO-2006125592-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS D.D. (SI) | 2006-11-30 | — | — | WO | claimed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| EP-3204362-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055582-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2016-04-14 | — | — | WO | disclosed |
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | disclosed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | disclosed |
| EP-1885714-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK Pharmaceuticals D.D. (SI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125592-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS D.D. (SI) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | DCTPP1, ENPP1, PPA1 | AGTR1 539/4885ABCB11 92/4885EGFR 4644/4885 |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | AGTR1, AGTR2, REN | AGTR1 1/4885ABCB11 4004/4885EGFR 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.